Half Year 2025 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Key Points
- Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million.
- The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income.
- Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates.
- The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics.
- Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections.
- The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year.
- The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer.
- R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs.
- The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions.
- Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results.
Gentlemen, welcome to the Basilia Pharmaceutica House Results 2025 conference call and live webcast. I am Sandra, the course call operator.
I would like to remind you that all participants have been in this synonym mode and the conference is being recorded.
The presentation will be followed by a Q&A session. You can register for questions at any time by pressing and one on your telephone. For operator assistance, please press star and 0.
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to David Lee, Chief Executive Officer. Please go ahead, sir.
Thank you.
Hello, I'm David Veitch, CEO of Bazilaya.
Thank you for joining us today on our conference call and webcast. We, we're going to review our financial results and key achievements for the first half year 2025, as well as highlight our priorities going forward.
For further detailed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
